A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

FDA Agrees to Expanded Access Program for the BioVentrix® Revivent TC System for the Treatment of Ischemic Heart Failure

BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure, today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.

The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar, who have a suboptimal response to guideline-directed medical therapy. The procedure, referred to as Less Invasive Ventricular Enhancement (LIVE®) therapy, utilizes myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber.

The approval for an Expanded Access Program follows the successful completion of enrollment in the ALIVE (American Less Invasive Ventricular Enhancement) Trial, a prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System. Enrollment in the ALIVE Trial was completed in April 2022.

“The Expanded Access Program is a significant step for BioVentrix as we continue to build our real-world evidence to treat a dilated left ventricle, a maladaptive consequence of cardiac remodeling in ischemic and non-ischemic heart failure,” said Jim Dillon, President and CEO of BioVentrix. “Heart failure patients with reduced ejection fraction (HFrEF) that are not responsive to standard-of-care therapies may now have access to LIVE Therapy, currently under investigation.”

“While awaiting data analysis and US regulatory submission from the pivotal approval ALIVE Trial, enrollment in the Expanded Access Program will allow ongoing usage of the device and new insights into the predictors and magnitude of improvement of high-risk patients with heart failure undergoing the LIVE Procedure,” said Gregg W. Stone, MD, Co-Principal Investigator of the ALIVE Trial, Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine and Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai, New York.

“Expanded access that permits ongoing usage of this investigational device is critically important,” said Jerry D. Estep, MD., Co-Principal Investigator for the ALIVE Trial and Chair of Cardiology, Cleveland Clinic Florida. “Patients with heart failure with high-risk features including significant shortness of breath despite medical management remain at high risk for disease progression and life-threatening events.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy